FMP

FMP

Enter

IDYA - IDEAYA Bioscien...

photo-url-https://images.financialmodelingprep.com/symbol/IDYA.png

IDEAYA Biosciences, Inc.

IDYA

NASDAQ

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

23.14 USD

-0.01 (-0.04322%)

Historical Prices

From:

To:

About

ceo

Mr. Yujiro S. Hata

sector

Healthcare

industry

Biotechnology

exchange

NASDAQ

Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patie...

CIK

0001676725

ISIN

US45166A1025

CUSIP

45166A102

Address

7000 Shoreline Court

Phone

650 443 6209

Country

US

Employee

124

IPO Date

May 23, 2019

Financial Statement

Earnings

IDYA Financial Summary

CIK

0001676725

Exchange

NASDAQ

Industry

Biotechnology

Sector

Healthcare

CUSIP

45166A102

ISIN

US45166A1025

Country

US

Price

23.14

Beta

0.86

Volume Avg.

901.98k

Market Cap

2B

Shares

-

52-Week

22.1-47.735

DCF

-0.51

ROE

-

ROA

-

Operating Margin

-

Debt/Equity

-

P/E

-9.93

P/B

-

Website

https://www.ideayabio.com

Upgrades and Downgrades

We are unable to load the data!

fmp-logo

Latest IDYA News

Davit Kirakosyan

Sep 23, 2024

Brookfield Asset Management’s Buy Rating Maintains at TD Cow...

BTIG analysts reiterated a Buy rating and maintained a $62.00 price target for Ideaya Biosciences (NASDAQ:IDYA) following the company's latest data update on its co-sponsored trial of darovasertib in neoadjuvant uveal melanoma (UM), along with insights into its Phase 3 strategy. The analysts emphasized that darovasertib appears to be a breakthrough treatment in the neoadjuvant setting, with data showing it preserves patients' eyes in up to 61% of cases. A key opinion leader (KOL) on the investor...

PRNewsWire

Aug 26, 2024

IDEAYA Biosciences to Participate in the Morgan Stanley 22nd...

SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference.

Zacks Investment Research

Jul 23, 2024

How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall S...

The mean of analysts' price targets for IDEAYA Biosciences (IDYA) points to a 33% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

MarketBeat

Jul 15, 2024

Positive News is Driving This Cancer Drug Maker's Stock High...

Shares of IDEAYA Biosciences Inc. NASDAQ: IDYA are up more than 16% after announcing positive treatment data for its Phase 2 clinical trial. The company's pipeline candidate, IDE397, is an experimental drug designed to treat certain bladder and small-cell lung cancers.

Zacks Investment Research

Jul 9, 2024

IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Da...

IDEAYA (IDYA) gains 15% on positive clinical data from its phase II study evaluating the 30 mg monotherapy expansion dose of IDE397 to treat MTAP-deletion urothelial and NSCLC patients.

Zacks Investment Research

Jul 9, 2024

Strength Seen in IDEAYA Biosciences (IDYA): Can Its 15.3% Ju...

IDEAYA Biosciences (IDYA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Benzinga

Jul 8, 2024

IDEAYA Biosciences Highlights 'Encouraging' Preliminary Effi...

Monday, IDEAYA Biosciences Inc IDYA released clinical data for the IDE397 Phase 2 monotherapy expansion dose in methylthioadenosine phosphorylase-deletion urothelial and non-small cell lung cancer patients (NSCLC).

PRNewsWire

Jul 5, 2024

IDEAYA Announces Investor Webcast to Report Clinical Data Up...

SOUTH SAN FRANCISCO, Calif. , July 5, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that the company plans to issue a pre-market press release and conduct an investor webcast on Monday, July 8, 2024, at 8:00 a.m.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedinfacebookinstagram
2017-2024 © Financial Modeling Prep